LifeVantage Corporation Stock price

Equities

LFVN

US53222K2050

Pharmaceuticals

Market Closed - Nasdaq 04:00:00 2024-03-27 pm EDT 5-day change 1st Jan Change
6.21 USD +0.49% Intraday chart for LifeVantage Corporation -10.78% +3.50%
Sales 2024 * 209M Sales 2025 * 220M Capitalization 79.91M
Net income 2024 * - Net income 2025 * - EV / Sales 2024 * 0.27 x
Net cash position 2024 * 23.16M Net cash position 2025 * 29.81M EV / Sales 2025 * 0.23 x
P/E ratio 2024 *
-
P/E ratio 2025 *
-
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 83.72%
More Fundamentals * Assessed data
Dynamic Chart
Transcript : LifeVantage Corporation - Special Call
LifeVantage Corporation Announces the Launch of its TrueScience Activated Skin Care Collection CI
Bradley Louis Radoff and Sudbury Capital Management Enter into Cooperation Agreement with LifeVantage Corporation CI
LifeVantage Corporation Appoints Dayton Judd to Its Board of Directors, Audit Committee and the Nominating and Corporate Governance Committee CI
LifeVantage Corporation Announces Expansion of LV360 into Canada, Mexico, and European Markets CI
Lifevantage Keeps Quarterly Cash Dividend at $0.035 a Share, Payable March 15 to Holders of Record March 1 MT
Transcript : LifeVantage Corporation, Q2 2024 Earnings Call, Jan 30, 2024
Earnings Flash (LFVN) LIFEVANTAGE CORPORATION Reports Q2 Revenue $51.6M, vs. Street Est of $54.6M MT
Earnings Flash (LFVN) LIFEVANTAGE CORPORATION Reports Q2 EPS $0.10 MT
LifeVantage Corporation Provides Earnings Guidance for the Fiscal Year 2024 CI
Tranche Update on LifeVantage Corporation's Equity Buyback Plan announced on November 27, 2017. CI
LifeVantage Corporation Declares Quarterly Dividend, Payable on March 15, 2024 CI
LifeVantage Corporation Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023 CI
Key Inflation Data Awaited as Exchange-Traded Funds, Equity Futures Rise Pre-Bell Thursday MT
Lifevantage Says Protandim Nrf2-TrueScience Combination Helps Cells 'Accurately' Respond To Stress Levels MT
More news

Latest transcript on LifeVantage Corporation

1 day+0.49%
1 week-10.78%
Current month-8.94%
1 month-9.61%
3 months+1.31%
6 months-4.90%
Current year+3.50%
More quotes
1 week
6.06
Extreme 6.06
6.97
1 month
6.06
Extreme 6.06
7.08
Current year
5.22
Extreme 5.22
7.23
1 year
3.04
Extreme 3.04
8.69
3 years
3.04
Extreme 3.04
9.78
5 years
3.04
Extreme 3.04
17.25
10 years
1.40
Extreme 1.4
17.25
More quotes
Managers TitleAgeSince
Chief Executive Officer 65 17-03-12
Director of Finance/CFO - 21-10-24
Compliance Officer - 08-10-31
Members of the board TitleAgeSince
Director/Board Member 72 11-12-31
Director/Board Member 64 19-05-05
Chairman 61 17-01-31
More insiders
Date Price Change Volume
24-03-27 6.21 +0.49% 13,934
24-03-26 6.18 -1.44% 37,946
24-03-25 6.27 -9.13% 47,993
24-03-22 6.9 -0.43% 13,131
24-03-21 6.93 -0.43% 18,419

Delayed Quote Nasdaq, March 27, 2024 at 04:00 pm EDT

More quotes
LifeVantage Corporation is engaged in the identification, research, development, formulation and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care, bath and body, and targeted relief products. The Company's dietary supplements include its flagship Protandim family of products, LifeVantage Omega+, ProBio, IC Bright, and Daily Wellness dietary supplements. The Protandim product line includes Protandim NRF1 Synergizer, Protandim Nrf2 Synergizer, and Protandim NAD Synergizer. TrueScience is its line of skin, hair, bath and body, and targeted relief products. The Company also markets and sells Petandim, its companion pet supplement formulated to combat oxidative stress in dogs; Axio, its nootropic energy drink mixes, and PhysIQ, its smartweight management system, which includes PhysIQ Fat Burn and PhysIQ Prebiotic, all formulated to aid in weight management.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings

Quarterly revenue - Rate of surprise

  1. Stock
  2. Equities
  3. Stock LifeVantage Corporation - Nasdaq